<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02561234</url>
  </required_header>
  <id_info>
    <org_study_id>CAEB1102-100B</org_study_id>
    <nct_id>NCT02561234</nct_id>
  </id_info>
  <brief_title>A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aeglea Biotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aeglea Biotherapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first-in-human study of the safety of increasing dose levels of AEB1102 in
      patients with advanced cancers. The study will also evaluate the amounts of AEB1102 in blood,
      the effects of AEB1102 on blood amino acid levels and tumor growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase I/2 multiple dose, dose escalation study utilizing a classic 3+3 design.
      Sequential cohorts of patients will receive AEB1102 IV weekly at one of a series of
      increasing dose levels. Dose escalation will be dependent on the frequency of specific
      dose-limiting toxicities in the prior cohort of patients. The study will determine the
      maximum tolerated dose (MTD) of AEB1102, evaluate the safety profile of the compound, assess
      the pharmacokinetic profile of AEB1102, determine the effect of AEB1102 on blood arginine
      levels and evaluate the anti-tumor activity of AEB1102.

      Following the determination of the MTD, additional cohorts of patients with uveal, cutaneous
      melanoma and small cell lung cancer will be enrolled and treated with AEB1102 at the MTD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">May 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum tolerated dose</measure>
    <time_frame>4 weeks</time_frame>
    <description>the dose level at which no more than 1/6 patients experiences dose-limiting toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety profile (changes in physical exam, laboratory measures, reported adverse events)</measure>
    <time_frame>4 weeks +</time_frame>
    <description>changes in physical exam, laboratory measures, reported adverse events</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Advanced Cancers</condition>
  <arm_group>
    <arm_group_label>AEB1102 Dose Escalation Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 patients dosed at 0.01 mg/kg until MTD determined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AEB1102 Dose Escalation Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 patients dosed at 0.02 mg/kg until MTD determined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AEB1102 Dose Escalation Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 patients dosed at 0.04 mg/kg until MTD determined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AEB1102 Dose Escalation Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 patients dosed at 0.08 mg/kg until MTD determined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AEB1102 Dose Escalation Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 patients dosed at 0.12 mg/kg until MTD determined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AEB1102 Dose Escalation Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 patients dosed at 0.18 mg/kg until MTD determined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AEB1102 Dose Escalation Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 patients dosed at 0.27 mg/kg until MTD determined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AEB1102 Dose Escalation Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 patients dosed at 0.40 mg/kg until MTD determined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AEB1102 Dose Escalation Cohort 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 patients dosed at 0.33 mg/kg until MTD determined MTD determined at 0.33 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AEB1102 Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Uveal: 11 patients dosed at 0.33 mg/kg Cutaneous Melanoma: 11 dosed at 0.33 mg/kg SCLC: 13 patients dosed at 0.33 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Co-ArgI-PEG</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>AEB1102 Dose Escalation Cohort 1</arm_group_label>
    <arm_group_label>AEB1102 Dose Escalation Cohort 2</arm_group_label>
    <arm_group_label>AEB1102 Dose Escalation Cohort 3</arm_group_label>
    <arm_group_label>AEB1102 Dose Escalation Cohort 4</arm_group_label>
    <arm_group_label>AEB1102 Dose Escalation Cohort 5</arm_group_label>
    <arm_group_label>AEB1102 Dose Escalation Cohort 6</arm_group_label>
    <arm_group_label>AEB1102 Dose Escalation Cohort 7</arm_group_label>
    <arm_group_label>AEB1102 Dose Escalation Cohort 8</arm_group_label>
    <arm_group_label>AEB1102 Dose Escalation Cohort 9</arm_group_label>
    <arm_group_label>AEB1102 Expansion</arm_group_label>
    <other_name>AEB1102</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For patients participating in any part of the trial:

          -  has an advanced solid tumor previously treated with, or inability to tolerate,
             standard therapy for the disease, or for which a standard therapy does not exist, and
             as such is considered a candidate for Phase 1 treatment

          -  has adequate organ function: Hgb ≥9 g/dL; absolute neutrophil count (ANC) ≥ 1.5x109/L;
             plt ≥ 100,000/μL; AST and ALT &lt; 2.5x ULN (&lt; 5x ULN in patients with liver metastases);
             total bilirubin &lt; 2.0 mg/dL; serum creatinine ≤ 1.5x ULN

          -  ECOG performance score 0-2

        For patients participating in any expansion group:

          -  has measurable disease based on RECIST 1.1 as determined by the treating investigator.
             Tumor lesions in a previously irradiated area are considered measurable if progression
             has been demonstrated in such lesions

          -  willing to consent for biopsy is strongly recommended but not mandatory

          -  recovery of toxicities related to any prior treatments to at least Grade 1 by CTCAE v
             4.03. Exceptions are patients with adverse event(s) that are clinically nonsignificant
             and/or stable on supportive therapy.

        For patients participating in specific expansion groups:

        Cutaneous Melanoma:

          -  unresectable, locally advanced or metastatic (AJCC stage IIIB, IIIC, or IV) cutaneous
             malignant melanoma

          -  relapsed or progressive disease after or unable to tolerate at least one prior
             systemic anticancer regimen for metastatic disease involving immunotherapy (anti-PD-1,
             anti-PD-L1, or anti-CTLA-4)

          -  in tumors with a relevant BRAF mutation, relapsed, refactory, or unable to tolerate at
             least one prior systemic anticancer regimen for metastic disease involving a BRAF
             inhibitor

        Uveal Melanoma:

          -  uveal melanoma at metastic stage

        Small Cell Lung Cancer:

          -  extensive disease previously treated with, or inability to tolerate, platinum-based
             chemotherapy

        Exclusion Criteria:

          -  has primary CNS malignancy

          -  history of untreated brain mets or leptomeningeal disease or spinal cord compression

          -  effects of prior anticancer therapy recovered to grade &lt; 2

          -  known HIV

          -  active infection

          -  major surgery within 2 weeks

          -  history of another malignancy within 2 years prior
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Joffrion</last_name>
    <role>Study Director</role>
    <affiliation>Aeglea Biotherapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pinnacle Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center: Mid Florida Hematology/Oncology Centers</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>93110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UTSW</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 25, 2015</study_first_submitted>
  <study_first_submitted_qc>September 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2015</study_first_posted>
  <disposition_first_submitted>August 14, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>August 14, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 19, 2019</disposition_first_posted>
  <last_update_submitted>October 4, 2019</last_update_submitted>
  <last_update_submitted_qc>October 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

